Stocks of Pulmonx Corporation (NASDAQ:LUNG) traded higher last session on Wall Street, down -0.97% to $13.23.
According to the data, Pulmonx Corporation (NASDAQ:LUNG) has 7 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $31.00 and a low of $19.00, we find $23.00. Given the previous closing price of $13.36, this indicates a potential upside of 72.16 percent. LUNG stock price is now -22.16% away from the 50-day moving average and -35.18% away from the 200-day moving average. The market capitalization of the company currently stands at $498.11M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
A total of 4 analysts have issued a hold rating and 3 have given it a buy rating. Brokers who have rated the stock have averaged $23.57 as their price target over the next twelve months.
With the price target reduced from $23 to $19, Citigroup Downgraded its rating from Buy to Neutral for Pulmonx Corporation (NASDAQ: LUNG)., while ‘Piper Sandler’ rates the stock as ‘Overweight’.
In other news, French Glendon E. III, President and CEO sold 25,000 shares of the company’s stock on Sep 15. The stock was sold for $500,000 at an average price of $20.00. Upon completion of the transaction, the President and CEO now directly owns 1,027,944 shares in the company, valued at $13.6 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 01, Chief Financial Officer Sung Derrick sold 1,082 shares of the business’s stock. A total of $19,335 was realized by selling the stock at an average price of $17.87. This leaves the insider owning 253,815 shares of the company worth $3.36 million. Insiders disposed of 251,811 shares of company stock worth roughly $3.33 million over the past 1 year. A total of 4.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LUNG stock. A new stake in Pulmonx Corporation shares was purchased by JEFFERIES GROUP LLC during the first quarter worth $11,840,000. SQUAREPOINT OPS LLC invested $1,583,000 in shares of LUNG during the first quarter. In the first quarter, DIMENSIONAL FUND ADVISORS LP acquired a new stake in Pulmonx Corporation valued at approximately $1,047,000. DYNAMIC TECHNOLOGY LAB PRIVATE LTD acquired a new stake in LUNG for approximately $768,000. QUBE RESEARCH & TECHNOLOGIES LTD purchased a new stake in LUNG valued at around $723,000 in the second quarter.
Tuesday’s opening bell rang with an opening price of $13.62 for Pulmonx Corporation (NASDAQ: LUNG). During the past 12 months, Pulmonx Corporation has had a low of $12.89 and a high of $45.49. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 9.40, and a quick ratio of 8.50. The fifty day moving average price for LUNG is $17.00 and a two-hundred day moving average price translates $20.41 for the stock.
The latest earnings results from Pulmonx Corporation (NASDAQ: LUNG) was released for Mar, 2022. According to the Medical Devices Company, earnings per share came in at -$0.43, missing analysts’ expectations of -$0.37 by -0.06. This compares to -$0.36 EPS in the same period last year. The company reported revenue of $13.95 million for the quarter, compared to $12.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.32 percent. For the current quarter, analysts expect LUNG to generate $13.73M in revenue.
Pulmonx Corporation(LUNG) Company Profile
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
